SARS-CoV-2: The Path of Prevention and Control-Reference-Cited by-同舟云学术

SARS-CoV-2: The Path of Prevention and Control

Published:2021-05 Issue:3 Volume:21 Page:358-362
ISSN:1871-5265
Container-title:Infectious Disorders - Drug Targets
language:en
Short-container-title:IDDT

Author:

Mohamed Amal A.¹,Mohamed Nouran²,Mohamoud Seham³,Zahran Fawkia E.⁴,Khattab Rania Abdelmonem⁵,El-Damasy Dalia Ali⁶,Alsayed Eman⁷,Abd-Elsalam Sherief⁸

Affiliation:

1. Department of Biochemistry, National Hepatology Tropical Medicine Research Institute, Cairo,Egypt

2. Faculty of Biotechnology, Misr University for Science and Technology, Cairo,Egypt

3. Tropical Medicine Department, Elsahel Teaching Hospital, Cairo,Egypt

4. Internal Medicine Department, Faculty of Medicine (Girls), Al -Azhar University, Cairo,Egypt

5. Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo,Egypt

6. Department of Microbiology, Faculty of Pharmacy, Egyptian Russian University, Cairo,Egypt

7. Department of Clinical Pathology, Minia University Hospital, Minia,Egypt

8. Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta,Egypt

Abstract

The 2019 coronavirus pandemic (COVID-19) continues to expand worldwide. Although the number of cases and the death rate among children and adolescents are reported to be low compared to adults, limited data have been reported. We urgently need to find the treatment and vaccine to stop the epidemic. Vaccine development is in progress, but any approved and effective vaccine for COVID-19 will take at least 12 to 18 months. The World Health Organization (WHO), the Center for Disease Control and Prevention (CDC), and the Food and Agriculture Organization (FAO) have issued instructions and strategies for controlling COVID-19 outbreak to the general public, physicians, travelers and injured patients to follow so that the transmission to a healthy population can be prevented. In this review, we summarize demographic data, clinical characteristics, complications and outcomes and finally prevention and control strategies for this serious pandemic.

Publisher

Bentham Science Publishers Ltd.

Subject

Microbiology (medical),Pharmacology,Molecular Medicine,General Medicine

Reference53 articles.

1. WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) Available from: 2020

2. Rivers C.; Chretien J-P.; Riley S.; Pavlin J.A.; Woodward A.; Brett-Major D.; Maljkovic Berry I.; Morton L.; Jarman R.G.; Biggerstaff M.; Johansson M.A.; Reich N.G.; Meyer D.; Snyder M.R.; Pollett S.; Using “outbreak science” to strengthen the use of models during epidemics. Nat Commun 2019,10(1),3102

3. Morgan O.; How decision makers can use quantitative approaches to guide outbreak responses. Philos Trans R Soc Lond B Biol Sci 2019,374(1776),20180365

4. Xu B.; Kraemer M.U.G.; Xu B.; Gutierrez B.; Mekaru S.; Sewalk K.; Kraemer M.; Open access epidemiological data from the COVID-19 outbreak. Lancet Infect Dis Open COVID-19 Data Curation Group2020,3099(20),30119-5

5. Sun K.; Chen J.; Viboud C.; Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digit Health 2020,2(4),e201-e208

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Updated and Focused Review on Heterocyclic Inhibitors for SARSCoV and SARS-CoV-2 3CLpro;Mini-Reviews in Medicinal Chemistry;2023-03

2. The Impact of LEP rs7799039 Polymorphism and Obesity on the Severity of Coronavirus Disease-19;Diabetes, Metabolic Syndrome and Obesity;2023-02

3. Human ACE-2, MCP1 and micro-RNA 146 as Novel Markers for COVID- 19 Affection and Severity;Infectious Disorders - Drug Targets;2023-02

4. MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?;Infectious Disorders - Drug Targets;2023-02

5. Corticosteroids: A boon or bane for COVID-19 patients?;Steroids;2022-12